MRI-guided transrectal prostate laser ablation for benign prostatic hypertrophy: a retrospective cohort study

Area of Science:

• Urology
• Minimally Invasive Surgery
• Medical Imaging

Background:

• Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms (LUTS).
• Transrectal laser ablation offers a minimally invasive treatment option for BPH.
• MRI guidance enhances precision in transrectal procedures.

Purpose of the Study:

• To evaluate the safety and efficacy of MRI-guided transrectal laser ablation for BPH-related LUTS.
• To assess symptom improvement and adverse events following the procedure.

Main Methods:

• A retrospective cohort study of 52 men with BPH treated with MRI-guided transrectal laser ablation.
• Data collected included patient demographics, prostate characteristics, and pre- and post-treatment symptom scores (IPSS, SHIM).
• Outcomes assessed were changes in IPSS and SHIM scores at 6, 12, and 24 months, and complication rates.

Main Results:

• Significant reductions in International Prostate Symptom Scores (IPSS) were observed at 6, 12, and 24 months post-ablation (p < 0.001).
• No significant difference in IPSS reduction was found between patients with and without prior BPH treatments (p = 0.628).
• Complications were predominantly Grade I (13.5%) and Grade II (23%), with no Grade III or higher events.

Conclusions:

• MRI-guided transrectal focal laser ablation is a safe and effective treatment for BPH-induced LUTS.
• The procedure leads to sustained symptom improvement over two years.
• The complication profile is favorable, with most events being minor.